Literature DB >> 35440653

Identification and characterization of novel endolysins targeting Gardnerella vaginalis biofilms to treat bacterial vaginosis.

Sara Arroyo-Moreno1,2, Matthew Cummings3, David B Corcoran3, Aidan Coffey2, Ronan R McCarthy4.   

Abstract

Bacterial vaginosis (BV) is a recurrent dysbiosis that is frequently associated with preterm birth, increased risk for acquisition of human immunodeficiency virus (HIV) and other sexually transmitted infections (STIs). The overgrowth of a key pathobiont, Gardnerella vaginalis, as a recalcitrant biofilm is central to the development of this dysbiosis. Overgrowth of vaginal biofilms, seeded by initial G. vaginalis colonization, leads to recurrent symptomatic BV which is poorly resolved by classically used antibiotics. In this light, the use of bacteriophages and/or their proteins, represents a promising alternative. Here we identify 84 diverse anti-Gardnerella endolysins across 7 protein families. A subset of 36 endolysin candidates were refactored and overexpressed in an E. coli BL21 (DE3) system and 5 biochemically and structurally diverse endolysins were fully characterized. Each candidate endolysin showed good lytic activity against planktonic G. vaginalis ATCC14018, as well as G. vaginalis clinical isolates. These endolysin candidates were assayed in biofilm prevention and disruption assays, with biofilm disruption at low microgram concentrations (5 μg/ml) observed. In addition to clonal G. vaginalis biofilms, endolysin candidates could also successfully disrupt polyspecies biofilms. Importantly, none of our candidates showed lytic activity against commensal lactobacilli present in the vaginal microbiota such as L. crispatus, L. jensenii, L. gasseri, and L. iners or against Atopobium vaginae (currently classified as Fannyhessa vaginae). The potency and selectivity of these novel endolysins constitute a promising alternative treatment to combat BV, avoiding problems associated with antibiotic resistance, while retaining beneficial commensal bacteria in the vaginal flora. The diverse library of candidates reported here represents a strong repository of endolysins for further preclinical development.
© 2022. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35440653      PMCID: PMC9018826          DOI: 10.1038/s41522-022-00285-0

Source DB:  PubMed          Journal:  NPJ Biofilms Microbiomes        ISSN: 2055-5008            Impact factor:   8.462


  48 in total

1.  Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori.

Authors:  B Björkholm; M Sjölund; P G Falk; O G Berg; L Engstrand; D I Andersson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

Review 2.  Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens.

Authors:  Vincent A Fischetti
Journal:  Int J Med Microbiol       Date:  2010-05-10       Impact factor: 3.473

3.  Hypnotherapy or medications: a randomized noninferiority trial in urgency urinary incontinent women.

Authors:  Yuko M Komesu; Ronald M Schrader; Rebecca G Rogers; Robert E Sapien; Andrew R Mayer; Loren H Ketai
Journal:  Am J Obstet Gynecol       Date:  2019-08-23       Impact factor: 8.661

Review 4.  Cell wall hydrolases and antibiotics: exploiting synergy to create efficacious new antimicrobial treatments.

Authors:  Michael Wittekind; Raymond Schuch
Journal:  Curr Opin Microbiol       Date:  2016-05-31       Impact factor: 7.934

5.  The PlyB Endolysin of Bacteriophage vB_BanS_Bcp1 Exhibits Broad-Spectrum Bactericidal Activity against Bacillus cereus Sensu Lato Isolates.

Authors:  Raymond Schuch; Adam J Pelzek; Daniel C Nelson; Vincent A Fischetti
Journal:  Appl Environ Microbiol       Date:  2019-04-18       Impact factor: 4.792

6.  Microtiter dish biofilm formation assay.

Authors:  George A O'Toole
Journal:  J Vis Exp       Date:  2011-01-30       Impact factor: 1.355

7.  Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus.

Authors:  Daniel B Gilmer; Jonathan E Schmitz; Chad W Euler; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

8.  In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens.

Authors:  Lucia Blasco; Anton Ambroa; Luis Martínez-Martínez; Maria Tomas; Rocio Trastoy; Ines Bleriot; Miriam Moscoso; Laura Fernández-Garcia; Elena Perez-Nadales; Felipe Fernández-Cuenca; Julian Torre-Cisneros; Jesus Oteo-Iglesias; Antonio Oliver; Rafael Canton; Tim Kidd; Ferran Navarro; Elisenda Miró; Alvaro Pascual; German Bou
Journal:  Sci Rep       Date:  2020-04-28       Impact factor: 4.379

9.  PHASTER: a better, faster version of the PHAST phage search tool.

Authors:  David Arndt; Jason R Grant; Ana Marcu; Tanvir Sajed; Allison Pon; Yongjie Liang; David S Wishart
Journal:  Nucleic Acids Res       Date:  2016-05-03       Impact factor: 16.971

10.  Thousands of Novel Endolysins Discovered in Uncultured Phage Genomes.

Authors:  Iris Fernández-Ruiz; Felipe H Coutinho; Francisco Rodriguez-Valera
Journal:  Front Microbiol       Date:  2018-05-18       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.